文献速递心外重症与机械循环支持

ISHLT机械辅助循环支持注册登记第三份年度报告:离心泵与轴流泵连续流左心室辅助装置的比较

Third Annual Report From the ISHLT Mechanically Assisted Circulatory Support Registry: A comparison of centrifugal and axial continuous-flow left ventricular assist devices.
PubMed 文献 · J Heart Lung Transplant · 2019-01-01

IMACS注册登记汇总分析了16286例耐用左心室辅助装置(LVAD)植入受者数据,比较轴流泵与离心泵受者的结局、不良事件及危险因素。两泵类型生存率相似,离心泵在消化道出血和血液相容性相关不良事件无事件生存方面优于轴流泵,全卒中或各卒中亚型无事件生存无显著差异。INTERMACS 1-3级占85%,目的地治疗与桥接治疗间存在生存差距,右心室辅助装置(RVAD)需求及延迟显著影响生存。

要点

  • 离心泵在消化道出血和血液相容性相关不良事件方面优于轴流泵
  • 两泵类型全卒中或各卒中亚型无事件生存无显著差异
  • RVAD需求及延迟显著影响生存,目的地治疗与桥接治疗存在生存差距

核心结论

  • 研究显示从轴流泵向离心泵的转变,四年生存率约60%。
  • 不良事件高发仍是这些技术更广泛应用障碍。
  • 未来综合研究终点考察生活质量和生存外不良事件可能有助于共享决策。

研究设计与样本

  • IMACS注册登记收集并分析来自4个集合体和24家个体医院的16286例LVAD受者数据。
  • 本第三份年度报告比较轴流泵与离心泵受者的结局、不良事件及危险因素。

主要发现

  • 轴流泵与离心泵LVAD受者基线特征存在显著差异。
  • 两泵类型生存率相似。
  • INTERMACS 1-3级占植入的85%。
  • 目的地治疗与桥接治疗患者间存在持续生存差距。
  • RVAD需求及延迟显著影响生存。

关键数值与推荐

  • 离心泵在消化道出血和血液相容性相关不良事件无事件生存方面优于轴流泵。
  • 两泵类型全卒中或各卒中亚型(出血性或缺血性)无事件生存无显著差异。

临床怎么用

  • 离心泵可能降低消化道出血和血液相容性相关不良事件风险。
  • 应关注RVAD需求及延迟对生存的显著影响。
  • 目的地治疗与桥接治疗间的生存差距需在决策中考虑。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The IMACS Registry compiles and analyzes worldwide data from patients undergoing implantation of durable left ventricular assist devices. METHODS: Data encompassing 16,286 LVAD recipients from 4 collectives and 24 individual hospitals was collected and analyzed. In this 3rd annual report we compare and contrast outcomes, adverse events and risks factors between axial flow and centrifugal flow device recipients. RESULTS: Significant differences were found in the baseline characteristics of axial vs centrifugal flow LVAD recipients. Survival was similar between pump types. INTERMACS profile 1-3 constitute 85% of implants. A survival gap persists in destination therapy compared to bridge patients. RVAD need and delay impact survival dramatically. Centrifugal flow outperforms axial flow recipients in regards to GI bleeding and freedom from hemocompatibility related adverse events. No significant difference in the actuarial freedom from all strokes or either stroke subtype (hemorrhagic or ischemic) was seen among the two types of pumps. New end points to guide decision making are proposed. CONCLUSIONS: We demonstrate a transition from axial to centrifugal flow with four-year survival that approximates 60%. A high frequency of adverse events remains an impediment to the wider adoption of these technologies. In the future, composite study endpoints examining life quality and adverse events beyond survival may help in shared decision making prior to MCS implant, and may provide the requisite data to support extension of MCS therapy into the lesser ill heart failure population.

来源:J Heart Lung Transplant,查看原文。版权归原作者所有。

引用

  1. Goldstein DJ, Meyns B, Xie R, et al. Third Annual Report From the ISHLT Mechanically Assisted Circulatory Support Registry: A comparison of centrifugal and axial continuous-flow left ventricular assist devices. J Heart Lung Transplant. 2019. PMID: 30945637. doi:10.1016/j.healun.2019.02.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。